Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Saint Regis Mohawk Tribe v. Mylan Pharmaceuticals Inc.
Case Number:
18-1638
Court:
Nature of Suit:
Companies
Government Agencies
Sectors & Industries:
-
January 01, 2019
Life Sciences Cases To Watch In 2019
The life sciences industry will be keeping an eye on courtrooms around the country in 2019, watching to see how the U.S. Supreme Court decides a legal battle over patent protection for drugs and monitoring the fallout from federal prosecutors' decision to spike a False Claims Act case. Here are seven cases life sciences attorneys say they'll be following in the coming year.
-
December 20, 2018
Biggest Native American Rulings In The 2nd Half Of 2018
A Texas federal judge sent shock waves through Indian Country in 2018 by striking down the Indian Child Welfare Act, while the Federal Circuit ruled against a New York tribe involved in a novel patent deal and a planned Connecticut tribal casino project suffered a major setback in federal court.
-
November 14, 2018
Fed Circ. Won't Stay Immunity Ruling For Allergan's Appeal
The Federal Circuit has said it wouldn't stay its ruling that sovereign immunity doesn't apply in inter partes reviews while Allergan PLC and the St. Regis Mohawk Tribe appeal to the U.S. Supreme Court.
-
November 06, 2018
Fed. Circ. Urged Not To Stay Immunity Ruling For Appeal
A trio of generic-drug makers have urged the Federal Circuit not to stay its ruling that sovereign immunity doesn't apply in inter partes reviews, arguing that Allergan PLC and the St. Regis Mohawk tribe haven't proven the U.S. Supreme Court would have a reason to take up their case or overturn the decision.
-
October 26, 2018
Allergan, Tribe Want IPRs Blocked As They Turn To High Court
Allergan PLC and the St. Regis Mohawk Tribe on Friday urged the Federal Circuit to stay its ruling that the tribe can face inter partes reviews as it takes the case to the U.S. Supreme Court, arguing that if it has to sit through patent challenges in the interim, its "sovereign immunity would be irretrievably lost."
-
October 22, 2018
Fed. Circ. Rejects Bid For PTAB Tribal Immunity Rehearing
The full Federal Circuit on Monday said it won't reconsider a panel's ruling that tribes can face Patent Trial and Appeal Board scrutiny, likely paving the way for one of the court's closest-watched cases to head to the U.S. Supreme Court.
-
September 19, 2018
No Need To Reconsider Immunity At PTAB, Fed. Circ. Hears
Mylan Pharmaceuticals Inc. and other generic-drug companies challenging Allergan PLC patents for dry-eye medication Restasis urged the full Federal Circuit on Tuesday not to reconsider an earlier decision that tribal sovereign immunity doesn't apply in reviews at the Patent Trial and Appeal Board.
-
September 07, 2018
States Back Tribe, Allergan Fed. Circ. Bid For PTAB Immunity
Seven states and two state universities urged the full Federal Circuit Friday to rehear a decision that tribal sovereign immunity doesn't apply in reviews at the Patent Trial and Appeal Board, saying the holding misreads the law and could subject patents owned by states to PTAB review.
-
August 20, 2018
Allergan, Tribe Want PTAB Immunity Denial Reheard En Banc
The Saint Regis Mohawk Tribe and Allergan PLC on Friday asked the Federal Circuit court to reconsider en banc its ruling last month that tribal sovereign immunity doesn't apply in reviews at the Patent Trial and Appeal Board, which rejected the drugmaker's attempt to shield patents for its dry-eye medication Restasis by transferring them to the Native American tribe.
-
July 20, 2018
Fed. Circ. Says Tribal Immunity Doesn't Apply In IPR
The Federal Circuit on Friday ruled tribal sovereign immunity doesn't apply in reviews at the Patent Trial and Appeal Board, rejecting an attempt from Allergan PLC to shield patents for its dry-eye medication Restasis by transferring them to a Native American tribe.